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ABSTRACT 
Background. Phenylketonuria (PKU) is an inherited metabolic disease that can be 
diagnosed and successfully treated early from birth with a phenylalanine-restricted dietary 
regimen. Nevertheless, PKU parents are found to be at risk for psychological and quality of 
life (QoL) maladjustments. In chronic illness, parental disturbances are found to influence 
adherence to treatments of their children. 
Objectives. The study aimed to: 1) evaluate the psychological issues and the quality of life 
of parents of PKU patients distinguishing the disease load from the treatment load; 2) 
assess if parental psychological functioning is related to blood phenylalanine (Phe) levels 
of their children, as indicators of metabolic control in relation to dietary compliance. 
Methods. The study is a cross-sectional study involving 146 parents of both patients with 
PKU (who need a phe-restricted dietary regimen) and patients with a mild form (mild 
hyperphenylalaninemia - MHP) who do not require a dietary treatment. Socio-
demographic data of both parents and patients together with patients’ clinical data 
(patient’s phenotype and patient’s Phe level) were retrieved. Self-report measures of 
psychological distress and symptoms (SCL-90-R), anxiety (STAI-Y), depression (BDI-2), 
anger (STAXI-2) and quality of life (SF-36) were collected. For aim 1, the means scores of 
all scales were compared to the appropriate normative samples; then, differences in 
SCL90-R, STAI, BDI-II, STAXI-II subscales and SF-36 dimensions mean scores between 
parents of PKU vs parents of MHP patients were tested through MANCOVA analyses, 
with socio-demographic variable as covariates in order to control for potential 
confounders. For aim 2, to assess if the parental psychological issues and quality of life can 
predict the dietary compliance, logistic regressions with a block entry method were 
performed. 
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Results. Globally, parents showed psychological characteristics and quality of life 
comparable to the normative sample; nevertheless, out of the normative cut off were the 
following (in brackets, percentage of parents): psychological distress (11,5%), state 
(25,3%) and trait (29,1%) anxiety, depressive symptoms (16,0%), hyper-control of anger 
expression (16,1%) and, as concern quality of life, Bodily pain (32,6%), General health 
(17,4%), Vitality (14,2%), Social functioning (27,7%), Emotional functioning (14,9%), 
and Mental health (20,6%). Mothers (vs fathers) and parents with a low (vs high) 
educational level showed statistically significant poor emotional outcomes. Parents of PKU 
(vs MHP) patients reported statistically higher values of depressive symptoms on the 
somatic-affective side and lower values of Physical activity and General health QoL scales.  
Patients optimal Phe levels were found to be predicted (R
2
=0,34, p=0.031) by the 
following parental psychological characteristics: high levels of depressive complaints on 
the somatic-affective side (=1.52, p=0.011) and low levels on the cognitive side (=0.59, 
p=0.050), high level of anger control (=0.77, p=0.043) and low level of anger expression 
outward (=1.35, p=0.032). Optimal Phe levels were predicted also by the following 
parental quality of life dimensions (R
2
=0,25, p=0.05): a lower Vitality (=0.93, p=0.035), a 
lower Social functioning (=0.94, p=0.027) and a higher Mental health (=1.07, p=0.043). 
Conclusions. Parenting patients with phenylketonuria do not generally affect 
psychological wellbeing and quality of life. Specific socio-demographic conditions are 
more at risk of disturbances; maladjustments are also related to the dietary management 
load and to the effort of maintaining an optimal adherence to diet of their children. Help 
children to remain adherent to the diet seems to affect the parents’ social functioning. 
Results are useful to help clinicians to identify specific situations at risk for non adherence 
and may have implications for setting up interventions to improve compliance to diet, 
together with parental and family wellbeing.  
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1. BACKGROUND 
1.1. Phenylketonuria: definition, causes, and consequences before the newborn 
screening 
Phenylketonuria (PKU) (PKU; OMIM 261600) is an autosomal recessive inborn error 
of metabolism, caused by mutations in a gene located on the long (q) arm of chromosome 
12 (Fig. 1.1). The gene codifies for the enzyme phenylalanine hydroxylase (PAH), which 
converts the amino acid phenylalanine to other essential compounds in the body.  
 
Figure 1.1. PAH gene locus 
 
More than 400 disease-causing mutations have been found in the PAH gene, leading to 
PAH deficiency and causing different spectrums of disorders, including classic 
phenylketonuria (PKU) and hyperphenylalaninemia (a less severe accumulation of 
phenylalanine). 
Phenylketonuria is classified as a metabolic disorder because of the deficient activity in 
the enzyme PAH responsible for converting the aminoacid phenylalanine (Phe) to tyrosine 
(Tyr) (Fig. 1.2).  
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Figure 1.2. Phenylalanine to Tyrosine conversion 
 
This enzyme is responsible for the majority of the catabolism of dietary phenylalanine 
and is located mainly in the liver (Fig. 1.3). 
 
Figure 1.3. Phenylalanine hydroxylating system (Blau et al., 2010) 
Loss of PAH activity, with consequently little or no conversion of phenylalanine to 
tyrosine, results in increased concentrations of phenylalanine in the blood and fluids 
throughout the body and toxic concentrations in the brain (Nussbaum et al., 2007), thus the 
catabolism of phenylalanine is blocked and serum levels of phenylalanine rise 
(hyperphenylalaninemia). 
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For individuals with PKU, elevated levels of Phe leads to damages of the central 
nervous system that can result in intellectual disability, seizures and spasticity. Several 
amino acids, including Phe, are important precursors used by the brain to create 
neurotransmitters (i.e. dopamine) (Figure 1.4).  
 
Figure 1.4. Phenylketonuria. 
 Lack of phenylalanine hydroxylase blocks the transformation of phenylalanine into tyrosine. 
Unmetabolized phenylalanine is shunted into the pathway that leads to the formation of phenylketones.  
Excess phenylalanine also inhibits formation of melanin from tyrosine. 
 
For these amino acids to reach their destination, they must cross over the blood-brain 
barrier (BBB). To cross the BBB specific amino acid transporters are shared by a variety of 
amino acids. As the blood Phe level increases, Phe saturates the transporter, increasing the 
amount of Phe crossing the BBB as well as decreasing the amount of other amino acids 
that use the same transporter (Pardridge, 1998). Although it is understood how Phe builds 
up in the body, the process by which it causes damage to the central nervous system has 
not yet been clarified (Nussbaum et al., 2007). 
6 
 
In any case, depending on the molecular genetics (see chapter 1.3), phenotypes can vary 
from a very mild increase in blood phenylalanine concentrations to a severe classic 
phenotype with pronounced hyperphenylalaninaemia, which, if untreated, results in 
profound and irreversible mental disability (Tab.1.1). In particular, untreated 
phenylketonuria is associated with progressive intellectual impairment, leading to 
progressive mental retardation, accompanied by a constellation of additional symptoms, 
which can include eczematous rash, albinism (excessively fair hair and skin) and 
hypopigmentation, a "musty odor" of baby's sweat and urine (due to phenylacetate, one of 
the ketones produced), autism, and motor deficits. Developmental problems and severe 
learning disabilities, aberrant behaviour and psychiatric symptoms (as hyperactivity or 
psychotic and depressive disorders) and seizures often become apparent as the child grows, 
and are the major clinical problems later in life. 
 
 
Table 1.1. Clinical features of untreated PKU 
  
Untreated PKU consequences
Microcephaly with progressive
impairment of cerebral function
Mental Disability with progressive
intellectual impairment
EEG abnormalities Seizures
Fail to obtain early developmental
milestones
Autism
"Musty odor" of baby's skin, hair,
sweat and urine (due to
phenylacetate accumulation)
Aberrant behaviour and psychiatric
symptoms
Albinism with excessively fair hair
and skin
Eczematous rash and tendency to
hypopigmentation
Motor Deficits Hyperactivity
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1.1.1 The newborn screening 
Until the 1960s, most children born with phenylketonuria became profoundly mentally 
disabled, often spending their lifetime in institutional care. The foundations for the early 
detection and modern management of phenylketonuria were laid by three key findings: 
Asbjorn Fölling (1934) identified raised levels of phenylalanine in the blood 
(hyperphenylalaninaemia) as the underlying cause of the neuropsychological deficits; 
Horst Bickel (1954) introduced a low-phenylalanine diet to treat Phenylketonuria; and in 
1962 Robert Guthrie introduced a diagnostic test suitable for mass screening for 
hyperphenylalaninaemia, in order to detect PKU before it become clinically symptomatic 
(the Guthrie test) (Fig. 1.5). 
 
Figure 1.5. The Guthrie Test 
 
Since the '60s , the newborn screening was gradually introduced in several countries 
(starting from the USA and Europe); most babies in developed countries are today 
screened for PKU soon after birth; PKU is in fact commonly included in the newborn 
screening panel of most countries, with varied detection techniques. Screening for PKU is 
performed on a newborn’s blood sample and done with bacterial inhibition assay (Guthrie 
test), immunoassays using fluorometric or photometric detection, or amino acid 
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measurement using tandem mass spectrometry (MS/MS). Measurements done using 
MS/MS determine the concentration of Phe and the ratio of Phe to tyrosine, both of which 
will be elevated in PKU. 
In most cases, after the routine newborn screening test (typically performed 2-7 days 
after birth, using samples drawn by neonatal heel prick), a repeat test is done at 
approximately two weeks of age to verify the initial test and uncover any phenylketonuria 
that was initially missed. 
If a child is not screened during the routine newborn screening test, the disease may 
present clinically with the characteristics previously described. 
In contrast, early diagnosis and prompt intervention with a dietary restriction has 
undoubtedly allowed most individuals with phenylketonuria to avoid severe mental 
retardation (Demirkol et al., 2011; Giovannini et al., 2012), though such clinical disorders 
in a mild form are still possible. 
 
1.1.2 The consequences after the newborn screening: early-treated PKU outcomes 
As said above, in PKU children, severe neurological and functional disorders can be 
prevented through an early strict dietary regimen aimed to reducing blood Phe to nontoxic 
levels (ranging from 120–360 μmol/L). However, minor structural changes in the brain 
have been shown in otherwise well-treated children with hyperphenylalaninemia, as well 
as neurocognitive, psycho-emotional and behavioural disturbances (Sullivan, 2001; van 
Spronsen et al., 2011; Bone et al., 2012; Sharman et al., 2012).  
Neurocognitive outcomes. Although the reasons are unknown, there are still 
individuals with PKU who exhibit some degree of neuropsychological dysfunction, even 
though they have had careful nutritional management (De Groot et al., 2010). For example, 
a meta-analysis of neuropsychological studies showed that adolescents and adults with 
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PKU perform significantly more poorly than matched controls without PKU on tests of 
both executive and nonexecutive functions (attention, inhibition, motor control and fine 
motor skills, perception/ visual spatial abilities and processing speed) with processing 
speed having the largest effect size (Moyle et al., 2007; Christ et al., 2010; Gentile et al., 
2010; Janzen & Nguyen, 2010).  
Educational achievement. Children with PKU span the full range of educational 
achievement but often perform less well at school than children without PKU, especially 
when metabolic control is suboptimal (Gassio et al., 2005). Poor performance in 
arithmetic/mathematics (Azen et al., 1991) and impaired ability to copy letters and 
geometrical designs, for example, are common.  
Behavioral, emotional, social disturbances and psychiatric disorders. Behavioral 
impairments and psychiatric symptoms are well documented across the lifespan of 
individuals with PKU, even those treated from infancy. Disturbances such as hyperactivity, 
anxiety, low self-esteem, and social withdrawal have been noted in children with PKU 
(Sharman et al., 2012; Sullivan & Change, 1999; Sullivan 2001;; van Spronsen et al., 2011; 
Weglage et al., 1992, 1994, 2000). Depressed mood, generalized anxiety, phobias, 
decreased positive emotions, social immaturity, agoraphobia, panic attacks, and social 
isolation have been reported especially during adulthood (Bone et al., 2012; Brumm et al., 
2010). Studies have reported rates of psychiatric issues among patients with PKU that were 
up to twice that of the general population (Burgard et al., 1994; Pietz et al., 1997). 
 
The etiology of the elevated rate of psychosocial maladjustment in phenylketonuria is 
not still clear; three hypotheses has been formulated to explain it: one based on biological 
factors, one on psychological considerations, and the other on the interaction between 
those two class of factors. 
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From the biological point of view, increased levels of phenylalanine may lead to a 
reduced synthesis of dopamine and serotonin in the brain of PKU patients, resulting in an 
imbalance of neurotransmitters and thus contributing to the pathogenesis of psychiatric 
disturbances (Jusiene & Kucinskas, 2004). Supporting studies showed a positive 
correlation between the degree of metabolic control and the severity of emotional disorders 
(Smith et al., 1988; Anjema et al., 2011; Sharman et al., 2012).  
The psychological perspective hypothesized that these problems are a consequence of 
living with a chronic condition rather than a biological effect of increased Phe levels. This 
perspective stresses the impact of an abnormal developmental condition and the burden of 
a strict and continuous dietary treatment (Feldmann et al., 2002; Weglage et al., 2000). 
Beyond the intra-child focus of most organic models, contemporary frameworks for 
studying child development increasingly emphasize the importance of interacting 
biological, social and psychological factors. Central to these current perspectives is the 
recognition of the family as the critical context of development for the young child. 
Parental involvement in PKU treatment is essential, because the parents are mostly 
responsible for the child maintaining a proper diet. In addition to the usual strain associated 
with caring for a newborn child, the parents of PKU children have to deal with two 
additional demands: 1) the grief and disappointment of having given birth to a sick child 
(i.e. parental feelings of guilt), 2) demands associated with learning to manage the diet.  
Distress and anxiety, common in PKU families especially in the first year, and a 
restrictive-controlling style of parenting is believed to contribute to the development of 
psychosocial maladjustment (Sullivan & Chang, 1999; Weglage et al., 2000). 
The third hypothesis tries to gather the other two perspectives pointing out the 
importance of the interaction between biological and environmental factors (Feillet et al., 
2010), for example how the parental and family features and strategies influence, predict or 
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protect PKU patients against the risk of developing mental and emotional difficulties due 
to their genetic predisposition. 
 
1.2 Epidemiology 
The occurrence of PKU varies worldwide. In Europe, the incidence is about 1/10,000 
births, but ranges from 1/4,000 in Turkey, to 1/100,000 in Finland. In Asia, the rates vary 
from 1/15,000 to 1/105,000 within China, to less than 1/200,000 in Thailand. The rates in 
Latin American range from 1/25,000 to 1/50,000, and the incidence in the United States is 
about 1/15,000 live births (Blau et al., 2010). In Italy the incidence is about 1/17,000 
(Williams et al., 2008).  
 
1.3 PKU genetics and classification 
PKU is known to be an autosomal recessive genetic disorder. This means both parents 
must have at least one mutated allele of the PAH gene and the child must inherit both 
mutated alleles, one from each parent. Therefore, it is not impossible for a parent with the 
disease to have a child without it if the other parent possesses one functional allele of the 
gene for PAH. The risk for two carriers to have an affected child is 25%, which leaves a 
75% chance with each pregnancy that their child will not be affected. Yet, a child from two 
parents with PKU will inherit two mutated alleles every time, and therefore the disease 
(Fig. 1.6). 
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Figure 1.6. Phenylketonuria inheritance by an autosomal recessive way 
 
The Human PAH Mutation Knowledgebase (PAHdb,) a database of naturally occurring 
mutations in the human PAH gene, was summarised in 2007 (Scriver, 2007) and includes a 
total of 548 separate mutations. The position and nature of the mutation dictates its effect 
on the activity of the PAH enzyme, which determines the severity of 
hyperphenylalaninaemia and the patient’s phenotype classification (Tab. 1.2). Various 
combinations of mutations result in a full spectrum of metabolic phenotypes, in which the 
three different classifications of PKU are dependent upon the severity and the amount of 
Phe within an individual’s blood before treatment has been started. The normal range of 
Phe in the blood is 50-110 μmol/L. Individuals with values of 120-360 μmol/L are 
considered to have mild hyperphenylalaninemia (MHP); these patients do not require 
dietary treatments. Individuals with a value of 360- 600 μmol/L are considered to have 
mild PKU, with a value of 600- 1200 μmol/L moderate PKU, and with values above 1200 
μmol/L classic PKU; all of these three phenotypes require dietary treatments. 
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Table 1.2. Metabolic Phenotypes of PKU based on blood Phe levels and treatment 
indication 
 
1.4 Treatment: the dietary management 
As just said, individuals who are diagnosed with PKU must follow a low Phe diet to 
prevent clinical disease manifestations from occurring, and to have optimal growth, 
development, and mental functioning while providing a nutritionally complete diet. The 
diet that individuals with PKU have to abide by is restrictive. Foods such as grain products, 
and all food derived from animals, need to be avoided, while others must be weighed 
before consumption, especially starchy vegetables. The diet does not only include making 
sure there are low levels of Phe being ingested, but also that proper levels of vitamins, 
minerals and essential fatty acids are being consumed.  
The goal of the diet is to maintain plasma concentrations of Phe within an acceptable 
range. The acceptable, or target, range for Phe levels varies throughout the world and 
across ages (Blau et al., 2010) (Tab. 1.3). 
PKU CLASSIFICATION
Metabolic phenotypes Blood Phe Treatment
Classic PKU >1200 μmol/l Dietary treatment
Moderate PKU 600–1200 μmol/l Dietary treatment
PKU mild 360 – 600 μmol/l Dietary treatment
Mild Hyperphenilalaninemia (MHP) (HPA) < 360 μmol/l No need to treat
14 
 
 
Table 1.3. Target blood phenylalanine concentrations (μmol/L) as recommended for 
treatment of phenylketonuria in different countries, by age grousp (Blau et al., 2010) 
 
The National Institutes of Health has recommended Phe blood levels for individuals 
with PKU who are younger than twelve and those who over twelve years of age. The 
normal value of Phe in an adult ranges from 43-80 μmol/L, the amount of Phe 
recommended for those under twelve is 120-360 μmol/L, and for those over twelve it is 
120-900 μmol/L, even if for adolescents Phe levels ranging between 120-600 μmol/L are 
recommended (National Institutes of Health Consensus Development Panel, 2001). 
For individuals who are on a low Phe diet, it is important to monitor their Phe levels to 
make sure they are remaining within their target zones. The monitoring of blood Phe levels 
is typically done through blood spot analysis. While there are recommended ranges, the 
ideal range for an individual will depend on their age, height and weight, and their bodies’ 
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ability to handle Phe. During infancy adjustments to an individual’s diet may need to be 
assessed weekly, whereas later, assessments will not have to occur as close together. Then 
again a low dietary compliance leads to cognitive and psycho-emotional disturbances 
(Sullivan & Change, 1999).  
Although there is data and support for the diet in individuals with PKU, there is limited 
knowledge on whether or not the diet is needed throughout their life. Those with PKU who 
were started early on with a low Phe diet are just now reaching middle age. The large 
majority of these individuals are neurologically healthy, but the possibility of neurological 
decline cannot be ruled out (Cleary, 2010). Among adult patients with PKU that claimed to 
be following their diet, 53% were found to be above the target level (Modan-Moses et al., 
2007); and those with Phe levels above target showed significantly improved reaction time 
and sustained attention after four to five weeks of strict diet control (Schmidt et al., 1994). 
The full impact of adhering to the diet in adulthood may not yet be understood, but for 
women who are pregnant, the importance of maintaining the diet is well known, as Phe can 
be transported across the placenta to the developing fetus, resulting in severe birth defects 
and developmental delay (Committee on Genetics, 2008). For women who have PKU, it is 
ideal for pregnancies to be planned, for them to have Phe levels under control before 
becoming pregnant, and maintaining a blood Phe level of 120-360 μmol/L for the duration 
of the pregnancy (Koch et al., 2010). 
 
Dietary restriction of phenylalanine remains the mainstay of treatment, thus an active 
area of research focuses on factors facilitating/preventing adherence to treatment; among 
them some are related to patients but many regard parents and family characteristics and 
functioning. In fact, patients and their families has to face various challenges across the 
lifespan, that vary as a function of the children’s developmental phases and the way they 
cope with them can influence compliance to diet and patients’ psychological well-being. 
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1.5 PKU management through the lifespan: patients and parents challenges 
The patient outcome is much more complex than the sole consequences of Phe levels on 
the brain. PKU will induce many disturbances in the family structure, and diet treatment by 
itself may have some specific burden to the individual with PKU and their family. The 
overall consequences of PKU extend beyond the disease itself. A recent review has 
explored and summarized the consequences and challenges of PKU throughout the lifespan 
(Feillet et al., 2010). 
Diagnosis announcement: from initial shock to reality 
The first step in PKU management following neonatal screening is the announcement of 
diagnosis. This is always a traumatic experience for parents, who have to come to terms 
with their baby’s health challenges ahead. Even after many years, when the child’s PKU is 
well managed and everyone in the family has adjusted to the new lifestyle, parents can still 
describe the terrible moment when the diagnosis was first announced (Lord et al., 2008). 
This initial shock of diagnosis is heightened since the baby with PKU initially appears to 
be in good health. The diagnosis may seem like a complete intrusion of the medical world 
into a family who was otherwise unprepared with no prior signals of a disturbance.  
From infancy and to the early school years 
The quality of metabolic control during infancy is strongly related to the children IQ, 
which is why a strict diet is recommended for the first 10 years of life. Nevertheless, even 
when metabolic control is maintained, some children experience attention deficit 
hyperactivity disorder (ADHD), which can lead to poor academic performance 
(Kalverboer et al., 1994; Salardi et al., 1992). The onset of ADHD may be due to a 
modifying gene known as MAO-B, which can trigger the increase of phenylethylamine (a 
toxic metabolite of Phe) when it is impaired (Ghozlan et al., 2004). Moreover, 
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neuropsychological studies have shown that children with PKU face some difficulties in 
mathematics (Pennington et al., 1985).  
Failure of PKU treatment may be related to parents’ inability to administer a low-Phe 
diet to their child. Reasons for failure can be attributed to parents and family functioning  
and backgrounds (Olsson & Montgomery, 2007; Shulman et al., 1991). Some parents 
cannot bring themselves to impose the diet on their child (Jusiene & Kucinskas, 2004). The 
success of parents in enforcing adherence to the diet often appears to parallel their general 
parenting skills. Those parents who are themselves accepting of the diet and view it as non-
negotiable with the child typically exhibit the greatest success. The stress of having to 
administer the diet can be worse on the family than the risk on the child’s health.  
During adolescence 
The main challenge in this view during the period of adolescence is the typical 
relaxation of the diet that occurs in this age group, regardless of the guidelines proposed by 
the medical team. There is an absence of perception of any immediate harm linked with a 
relaxed diet, and the benefit and pleasure of food becomes more important to the 
individual. The primary obstacles often cited to better adherence are time constraints and 
stress associated with food preparation and record-keeping, and the restrictions imposed on 
social life (Bilginsoy et al., 2005). These obstacles can be amplified by parental 
maladjustment to chronic illness (Jusiene & Kucinskas, 2004). 
Many studies have reported psychological disturbances in older children or adolescents 
with PKU (Weglage et al., 1992; Burgard et al., 1994; Weglage et al., 2000; Sullivan, 
2001; Jusiene et al., 2001). Internalizing problems such as depressive mood, anxiety, 
physical complaints, or social isolation are significantly more common in individuals with 
PKU, whereas externalizing problems are not (Burgard et al., 1994; Jusiene et al., 2001). 
Weglage et al. (1992; 2000) also showed that patients are characterized by less autonomy, 
more negative evaluation of their scholastic ability, less achievement motivation, low 
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frustration tolerance, more negative self-description, less extroversion and impulsiveness, a 
feeling of not being quite healthy, and feeling that they are less independent. Individuals 
with PKU may see their social situation as being distinctly restricted. These psychological 
attributes have been found equally in patients with diabetes and may be related to the 
burden of a chronic condition (Jusiene et al., 2001). 
During adulthood 
In adulthood, individuals with PKU face challenges that involve interpersonal 
relationships associated with the maintenance of their PKU diet, as well as the basic 
incompatibility between the PKU diet and many lifestyle demands (Frank et al., 2007). In 
women, one of the main behavioral goals, as explained above, is the prevention of an 
unplanned pregnancy.  
 
1.6 Phenylketonuria in families: the impact of PKU on parents 
Since PKU is an autosomal recessive disorder, it can be inferred that the parents of 
affected individuals are obligate carriers. Those who have only one PAH mutation (e.g., 
parents of a child with phenylketonuria, unaffected sibling) are carriers (Figure 1.7).  
 
Figure 1.7. Parents of PKU children are obligate carriers for PAH mutated allele 
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It is presumed that such individuals have below normal phenylalanine hydroxylase 
levels since it has been repeatedly demonstrated that carriers have a reduced tolerance to a 
phenylalanine load. Whether or not these persons share other biochemical characteristics 
with the homozygous phenylketonuric, such as reduced serotonin and catecholamine 
levels, has currently not been clarified. It has been suggested, that persons heterozygeous 
for phenylketonuria are more apt to suffer from psychopathology than other individuals 
(Penrose, 1935). However, the studies on psychological wellbeing of parents of PKU 
patients showed inconsistent results: various has found psychological and quality of life 
disturbances among parents and unaffected siblings of PKU patients (Fisch et al., 1981; 
Jusiene & Kucinskas, 2004; Kuznetsova, 1972; Lord et al., 2005, 2008; Mahmoudi-
Gharaei et al., 2011); but others highlighted that parents have a good psychological 
adjustment (Blumenthal, 1967; Fidika et al., 2013; ten Hoedt et al., 2011). 
It could be important to evaluate the impact of PKU on families and to clarify what can 
be the origin of these disturbances. Within this clarification effort, a theoretical model base 
on the perspectives used to explain patients’ psychological disorders could be applied also 
to parents. 
Within a biological perspective, if we think of PKU as an autosomal recessive disorder, 
parents are carriers, so it would be important to study the presence of emotional and 
behavioral problems related to being biologically heterozygous for PKU gene (a gene that 
altered the neurotransmitters involved in emotional and behavioral regulation, i.e. 
dopamine). This perspective would be coherent to a specific psychiatric literature that has 
focused on studying families who include individuals with psychiatric disorders (as 
schizophrenia, bipolar disorder or autism) to detect relatives who are carriers of the genes 
(or polymorphisms) involved in those disorder, and who showed smoothed manifestations 
of the clinical symptoms, traits associated with the clinical disorder (called 
endophenotypes). For example, a recent meta-analysis (Lavoie et al., 2013) has highlighted 
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that social cognition (mentalizing, emotional processing, social perception, social 
knowledge and/or attributional style, theory of mind) is globally affected in first-degree 
relatives of people with schizophrenia (who are carrier of specific polymorphisms), 
suggesting that social cognition deficits in schizophrenic families may be related to a 
genetic vulnerability for the disorder. 
From a psychosocial point of view, PKU can be seen as a chronic disease that requires a 
rigorous therapeutic treatment in which parental involvement is very heavy and 
burdensome, with potential implications for parents’ emotional distress and quality of life. 
Reoccurring health-related concerns or treatment adherence problems, together with 
feeling of guilty for transferring PKU gene (Eiser, 1985) and trauma reactions to the 
diagnosis or grief response to the loss of a normal healthy child (Ashton & Ashton, 2000) 
may constitute chronic stressors for parents (Streisand & Tercyak, 2004), challenge parents 
self efficacy, psychological wellbeing and quality of life. This perspective would be 
consistent with previous research showed that parents of chronically ill children (diabetes, 
asthma, cancer, etc) are at risk of developing psychological disorders and psychosocial 
problems and to have poorer health than parents of healthy children (Cohen, 1999) 
A systematic review of the literature regarding psychological issues among parents of 
PKU children has been conducted
1
. Here we illustrate the main thematic areas emerging 
from all the included studies (n=17) (Fig. 1.8). 
                                                          
1 
Borghi  et al. (2015). Psychological issues in parenting children with phenylketonuria. A systematic 
narrative review of the existing literature. Submitted manuscript. 
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Figure 1.8. Thematic issues emerging from a systematic review of the literature 
regarding psychological issues among parents of PKU patients 
 
We did not set any time constrain, in order to collect all the studies on the topic of 
interested; included studies ranged from 1967 to 2013. To note that the more dated studies 
regarded parents’ mental health within a biological perspective; then, studies focused 
mainly on parental relationships both in family and social networks; only recently, studies 
concerned parental strategies to manage and cope with PKU/diet and parental quality of 
life, shifting the focus towards a psycho-social perspective. 
 
  
30%
33%
11%
22%
4%
Management and coping 
with PKU/diet
Mental health
Quality of life
Family and social network
Be a gene carrier
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2. OBJECTIVES 
2.1 Need for this Study 
As regards parents of PKU children, there is only little knowledge about psychological 
adjustment and about the etiology of these potential disturbances, either they are 
considered to be manifestations of being a PKU carrier or reactions to have a child with a 
chronic disease. 
The information that will be learned from these families will help medical professionals 
provide a higher standard of care to these families by providing relevant information and 
by setting up interventions that are tailored to their needs. 
As regard PKU patients, the benefits of newborn PKU testing and being on a low Phe 
diet are known and understood. It is also known that patients with PKU may shows 
psychological maladjustment, that are partially related to non adherence to diet and 
resulting higher phenylalanine levels. Only a few studies, however, have explored the 
compliance to treatment of PKU children in the context of parent-related factors. Such 
investigations could shed some light on environmental factors that influence the patients’ 
blood phenylalanine levels and may covary with measures of psychological functioning 
across the lifespan (Sullivan & Chang, 1999). 
 
2.2 Hypothesis and Study Objectives 
This study seek to answer three main questions. The first is to determine if parents of 
children with phenylketonuria suffer from any psychological maladjustment compared to 
the general population. The second is consequent to the first, that is: if parents show 
psychological disturbances are them related to be a PAH gene carrier or to the stress of 
having a child with a chronic disease. This could be clarify comparing psychological issues 
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of parents of PKU children who need a chronic management of the illness (dietary 
treatment along the lifespan) with parents of MHP children that are always heterozygote 
for the mutated gene but whose children do not need dietary treatment. Finally, we would 
evaluate the role of parental psychological issues on blood phenylalanine levels, that are 
the results of compliance to diet and that could be related to patients psychological 
wellbeing. 
The study aims therefore are to: 
1) evaluate parents psychological issues and quality of life with two focus: 
a) among the whole population of PKU parents (compared to the normative scores for 
the general population) 
b) comparing those measures between parents of PKU children (who have to follow a 
phe-restricted dietary regimen) vs parents of MHP children (who not need to be treated) 
2) evaluate if parental psychological issues and quality of life predict blood Phe levels 
(dietary compliance) of their sons/daughters. 
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3. MATERIALS AND METHODS 
3.1 Participants 
Participants were consecutively recruited at the Clinic of Metabolic Disorder, 
Department of Paediatrics, San Paolo Hospital, Milan, from July 2013 to April 2015. 
The neonatal screening for HPA is obligatory by law in Italy since 05/02/1992, but 
executed in Lombardy up from 01/01/1977. Therefore, every newborn screened for 
hyperphenylalaninemia, if found to be positive, is sent to our centre for diagnosis 
confirmation; thus our centre is one of the main centres that provides management for 
children with PKU in Italy. 
The sample consisted of one or both parents from families with a child with PKU o 
MHP with no age limits. If families had more than one child with PKU within the age 
range, data were collected in relation to the younger child with PKU. 
Exclusion criteria were: parents’ psychiatric history and inability to understand Italian. 
 
3.2 Data collection 
Participants were recruited in the waiting room at the time of their children’s clinic visit 
at the outpatient for metabolic disorders of the Paediatric Department by a qualified 
psychologist researcher. Participating parents attended a single assessment session lasting 
about 60 min in which they were provided with a packet of self-report measures which 
they were asked to fully complete and return. 
Self-reported psychological data included measures of: psychological distress 
(Symptom Check List 90-R; State-Trait Anxiety Inventory; Beck Depression Inventory-II); 
aggressiveness and modality of anger management (State-Trait Anger Expression 
Inventory-II - STAXI), and quality of life (Short-Form Health Survey 36 - SF-36). Parents 
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and children socio-demographic were collected through a specific form; patients’ blood 
phenylalanine level of the visit in which parents filled out the questionnaires were retrieved 
from the medical records.  
The study protocol was approved by the San Paolo Hospital Ethics Committee. All 
participants gave informed written consent before entering the study. 
 
3.3 Measures and instruments 
 Parents socio-demographic data: parents’ age, relational status, educational level 
and professional condition were collected in order to control for possible 
confounders or to identify risk factors for the psychological assessment. 
 Patients’ data: patients’ age, gender and phenotype classification were also 
collected from medical records. Patients were divided in two groups:  
 Group 1: PKU patients who are individuals periodically monitored at our 
Department from diagnosis and who have started the dietary treatment 
within first six weeks of life based on Phe-free protein substitutes and 
vegetal foods with a low Phe content, according to their dietary 
requirements.  
 Group 2: MHP patients who were allowed to follow an unrestricted dietary 
regimen and recommended routine dietary advice as used for healthy 
children.  
Psychological issues - psychological distress, anxiety and depressive symptoms, 
aggressiveness and modality of anger management – and quality of life were evaluated by 
means of the following self-report scales. 
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 Psychological symptoms and distress (SCL-90-R) 
Parents’ psychological distress was measured using Symptom Checklist-90-
Revision (SCL-90-R), which is a multidimensional, self-report symptom inventory 
developed by Derogatis et al.(1976; 1994). The SCL-90-R (Derogatis et al., 1994: 
Sarno et al., 2011) is a 90 items questionnaire rated on a five-point Likert scale 
(ranging from "0=no problem" to "4=very serious"). It evaluates a broad range of 
psychological problems and symptoms of psychopathology clustered in 9 primary 
scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, 
anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism). It also includes 
3 Global Indices: Global Severity Index (GSI), designed to measure overall 
psychological distress; Positive Symptom Distress Index (PSDI), measuring the 
intensity of symptoms; Positive Symptom Total (PST), i.e. number of self-reported 
symptoms. Higher scores on scales and indexes of the SCL-90-R indicate higher 
distress. The Italian version of the questionnaire showed good internal coherence 
for all subscales (Cronbach alpha values between 0.70 and 0.96) (Prunas et al., 
2012).  
 
 Anxiety (STAI-Y) 
Parents anxiety issues were assessed using the Italian version (adapted by 
Pedrabissi & Santinello, 1989) of the State-Trait Anxiety Inventory-Form Y (STAI-
Y) (Spielberger et al., 1983). The questionnaire differentiates between temporary or 
emotional state anxiety and long standing personality trait anxiety in adults. The 
STAI-Y is therefore divided into two sections, each composed of twenty four-point 
Likert items: STAI-Y1 assesses state anxiety, that is the current psychological 
condition of each subject, whereas the STAI-Y2 investigates the trait anxiety, that 
is the subject’s usual state of mind. The Italian version of the STAI-Y has shown a 
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good internal consistency (Cronbach's alpha coefficient ranges from 0.91 to 0.95 
for the Y1 subscale and from 0.85 to 0.90 for the Y2 subscale) and a good test-
retest reliability (0.49 for the Y1 and 0.82 for the Y2 subscale) (Spielberger et 
al., 2012). 
 
 Depression (BDI-2) 
Parents depressive symptoms were evaluated using the Italian adaptation (Beck et 
al., 2006) Beck Depression Inventory-2nd Edition (BDI-2) (Beck et al., 1996), a 
21-item self-report inventory designed to assess the presence and severity of 
depressive symptoms in the past 2 weeks in clinical and nonclinical samples. It is 
rated on a 4-point Likert-type scale ranging from 0 to 3 based on severity of each 
item. Scores range from 0 (no symptoms) to 63 (very severe symptoms); total 
scores can be categorized as minimal (0–13), mild (14–19), moderate (20–28), and 
severe (29–63) (Beck et al., 1996). In the Italian version, a score of 12 has been 
identified as an optimal cut-off to discriminate individuals with and without 
problems of depression in the Italian population (Beck et al., 2006).  
The BDI-2 possesses excellent internal reliability (α = 0.90–0.92) and test-retest 
reliability (r=0.93) (Beck et al., 1996; Beck et al., 2006). 
The psychometric properties of the scale are supported in clinical and nonclinical 
samples by an extensive literature (Arbisi, 2001); its structure has been examined 
using factor analysis (Ward, 2006), revealing a two-factor solution that comprises a 
cognitive factor and a somatic-affective factor in non-clinical individuals (Beck et 
al., 2006). Separate scores for each factor were calculated for each participant. 
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 Anger and aggressiveness (STAXI-II) 
Participants’ state and trait anger and aggressiveness were evaluated using the 
State-Trait-Anger-Expression-Inventory-2nd Edition (STAXI-2; Spielberger, 
1999), which is a self-report questionnaire composed of 57-items on a 4-point 
scale. The instrument is composed of six scales, five subscales, and an Anger 
Expression Index, and they measure five different dimensions: how a person feels 
angry at a given moment (State-Anger), how frequently, easily, and intensely the 
person feels angry (Trait-Anger) and what the person does when feeling angry (e.g. 
express or control the anger) (Anger Expression-In, Anger Expression-Out, Anger 
Control-In, Anger Control-Out). Higher scores indicating higher levels of state and 
trait anger, and a prevalence on the modality to cope with anger. The Italian version 
has shown good validity and internal consistency (Cronbach's alpha coefficient 
ranges from 0.74 to 0.95) (Comunian, 2004). 
 
 Quality of life (SF-36) 
Parents’ quality of life (QoL) was assessed using the Italian version of the MOS 36-
Item Short Form Health Survey (SF-36) (Ware & Sherbourne, 1992; Apolone & 
Mosconi, 1998), a widely used and validated instrument containing a total of eight 
subscales, namely Physical Functioning (activity), Physical Role Functioning, 
Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role 
Functioning and Mental Health. The subscales scores range between 0 and 100, 
with lower scores indicating poorer QoL and a higher concern in the specific 
domain. The questionnaire shows good internal consistency for all the subscales 
(Cronbach's alpha values range from 0.77 to 0.93). In addition, the subscales are 
combined to yield two summary health status measures, the Physical Sum scale and 
the Psychological Sum scale (Ware & Sherbourne, 1992; Apolone et al., 2000). 
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 Dietary compliance indicator 
Patients’ blood phenylalanine levels of the day in which parents complete the self-
report scales were collected from medical records. Blood phenylalanine levels were 
determined by the Guthrie bacterial inhibition assay. Compliance was evaluated 
according to age adjusted reference threshold values of plasma Phe as suggested by 
Scriver; in particular, blood phenylalanine levels of PKU patients under dietary 
regimen (group 1) were considered indexes of compliance to diet if levels were 
<360 (for children under 13 yrs) and <600 (for children older than 13 years). 
Patients current Phe levels were considered as a representative index of metabolic 
control (Antshel et al., 2004) and an indicator of dietary compliance.  
 
3.4 Data analysis 
Preliminary analysis included a description of parents’ socio-demographic 
characteristics, patients socio-demographic and patients’ clinical data. Frequencies and 
percentages were used for discrete variables; means, standard deviations, and variances for 
continuous variables. 
Descriptive statistics were also performed to describe the parents’ psychological and 
QoL characteristics; t-tests and one-way ANOVA were used to compare psychological and 
QoL outcomes between different socio-demographic and clinical conditions.  
For all the continuous variables,  Skewness e Kurtosis were used to assess the normality 
of the distribution. When either the indexes were suboptimal, the removal of outliers was 
conducted until Skewness and Kurtosis values have reached sufficiently acceptable in 
order that parametric tests can be applied; when it was not possible to normalize the scales 
non-parametric tests were used.  
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For aim 1, differences in SCL90-R subscales, STAI, BDI-II, STAXI-II subscales and 
SF-36 dimensions mean scores between parents PKU patients vs parents of MHP patients 
were tested through MANCOVA analyses. Parents socio-demographic characteristics were 
used as covariates, in order to control to potential confounders. Patients’ phenotypes 
(divided in two groups: PKU vs MHP) and patients’ age were insert as independent 
variables.  
MANCOVA were performed for STAI, BDI, STAXI expression Subscales, ANCOVA 
were used for GSI SCL-90-R index and trait-STAXI, Kruskal-Wallis test was used for 
state-STAXI. 
For aim 2, to assess if the parental psychological issues and quality of life can predict 
the dietary compliance logistic regressions with a block entry method were conducted; 
Durbin-Watson test were performed in order to verify that the residual were not correlated 
(values has to range 1,5-2,5). 
Two-tailed statistical analysis was performed using SPSS for Windows 21.0 software 
(SPSS Inc., Chicago, IL, USA) with statistical significance set at a level of p ≤ 0.05. 
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4. RESULTS 
4.1 Preliminary analysis 
Parents contacted for the study were n=217, of which 88% (n=190) accepted the initial 
proposal and n=146 completed and returned all the questionnaires, resulting in a 68% 
response rate. Participating families involved 146 parents of 101 children. The non 
participating parents (n =27) did not differ significantly from the study sample when 
compared on available demographic data (patient age, patient gender, patient’s phenotype: 
PKU/MHP); fathers refuse more than mothers. Reasons for refusals were mostly the time 
commitment required for the study and the parents time constraints; another reason was the 
personal nature of the information sought. 
 
4.2 Socio-demographic and clinical characteristics of the sample  
The total sample consisted of n=146 parents of patients with phenylketonuria (n=101). 
The Parent Sample 
From 101 families, data were available for 86 mothers and 60 fathers.  
The mean age of mothers was 40.5 years (SD = 6.8, range 23–62 years), and the mean age 
of fathers was 43.6 years (SD=7.5, range 30–63 years). Mothers mean age was 
significantly lower than father one (t=2.5, p=0.012). Parents were mainly cohabiting or 
married, but 20% of them were single or divorced.  
Most of the mothers (76%, n=62) and fathers (97%, n = 58) had a professional condition; 
the majority had a high or graduate educational level (69%, n=57 of mothers and 64%, n = 
35 of fathers). While mothers and fathers did not differ for educational level (2=1.01, 
p=0.6), mothers were more frequently unemployed compared to fathers (2=11, p=0.001). 
Parents came from various regions of Italy.  
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The patient  sample 
Of the 101 patients, 52 were male and 49 were female. The mean age of the patients was 
8.8 years (SD=7.01, range = 1 month – 37 years).  
All children had a form of phenylketonuria. Just over half of patients (60%) had a 
diagnosis of classic/moderate PKU requiring phe-restricted dietary regimen and regular 
blood tests (group 1); 40% had MHP  requiring monitoring but no diet restriction (group 
2). 
 
4.3 Socio-demographic comparison between parents of PKU and of MHP patients 
There are no differences between parents of children requiring dietary treatment and 
parents of children requiring only to be monitored for the socio-demographic 
characteristics (Table 4.1). 
 Parents of 
PKU patients 
Parents of MHP 
patients 
p 
Relationship status, % (n) 
Single/divorced 
Cohabiting/married 
 
19 % (16) 
81 % (70) 
 
24 % (13) 
76 % (41) 
0.44 
Educational level, % (n) 
Primary 
High school  
Graduate  
 
30 % (25) 
49 % (40) 
21 % (17) 
 
38% (20) 
32 % (17) 
30 % (16) 
0.15 
Profession, % (n) 
Professional conditions 
Non professional conditions 
(housewives, students, unemployed) 
  
85 % (73) 
15 % (13) 
 
83 % (43) 
17 % (9) 
0.73 
 
Table 4.1 Comparison of socio demographic characteristics between  
parents of PKU patients and parents of MHP patients 
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4.4 Parents psychological issues and quality of life compared to the normative sample  
Parents’ mean scores of SCL-90-R, STAI, BDI-II and STAXI-II subscales and indexes 
were all within the normal ranges; nevertheless, some of them reported clinical 
psychological distress (GSI > 1), state and trait anxiety, depression and an extreme 
tendency to control the anger expression outward (Table 4.2). 
 
 
Table 4.2 Clinical psychological features of parents 
All the parents’ mean scores of the SF-36 subscales were also within the normal ranges; 
but some of them reported a poor quality of life in different domains, both on the physical 
and on the emotional field (Table 4.3). 
 
 
Table 4.3 Altered quality of life domains among  parents 
Mothers reported more psychological distress, were more anxious, depressed and angry 
and more frequently presented an altered quality of life in the domains of emotional well-
being than fathers (Figure 4.4-4.6) 
Psychological
distress
Anxiety Depression Anger control
Gobal Severity
Iindex 11,5% 
State Anxiety 25,3% 
Trait Anxiety 29,1% 
BDI 16% Control out 16,1%
Bodily pain General
health
Vitality Social 
functioning
Emotional
functioning
Mental
health
32,6% 17,4% 14,2% 27,7% 14,9% 20,6%
34 
 
 
Figure 4.4 Psychological disturbances among mothers and fathers 
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Figure 4.5 Anxiety, depression and anger among mothers and fathers 
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Figure 4.6 Quality of life among mothers and fathers 
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4.5 Comparison between parents of PKU patients and parents of MHP patients 
To evaluate differences in psychological issues and quality of life between parents of 
PKU patients (with a dietary regimen) and parents of MHP patients (without a diet 
restriction) MANCOVA analyses were performed; the patient’s phenotype (PKU vs MHP) 
and the patient’s age were set as independent variables, while parental socio-demographic 
characteristics as covariates. 
MANCOVA analyses, one with SCL-90-R subscales and one with SCL-90-R indexes as 
dependent variables, revealed no effects of socio-demographic characteristics (except for 
gender, in the direction described above), nor of the patient’s phenotype, the patient’s age 
or their interaction. 
MANCOVA analysis with STAI scales as dependent variables confirmed the effect of 
gender; no effect of the patient’s phenotype, the patient’s age and of their interaction was 
found. 
MANCOVA analysis with BDI subscales as dependent variables confirm the effect of 
gender, and found a significant effect of the educational level on the cognitive factor 
(lower-educated parents reported more depressive symptoms on the cognitive side 
compared to high-educated and graduated) and of the patient’s phenotype on the somatic-
affective factor of parental depression (Tables 4.4 – 4.7). 
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Table 4.4 Multivariate tests 
Effect   Value F 
Hypothesis 
df 
Error’s 
df Sig. 
Partial 
eta 
squared 
Intercept Pillai’s trace 0,037 2,144(a) 2,000 111,000 0,122 ,037 
  Wilks’ lambda 0,963 2,144(a) 2,000 111,000 0,122 ,037 
  Hotelling trace 0,039 2,144(a) 2,000 111,000 0,122 ,037 
  Roy’s largest root 0,039 2,144(a) 2,000 111,000 0,122 ,037 
Gender Pillai’s trace 0,064 3,777(a) 2,000 111,000 0,026 ,064 
  Wilks’ lambda 0,936 3,777(a) 2,000 111,000 0,026 ,064 
  Hotelling trace 0,068 3,777(a) 2,000 111,000 0,026 ,064 
  Roy’s largest root 0,068 3,777(a) 2,000 111,000 0,026 ,064 
Age Pillai’s trace 0,019 1,090(a) 2,000 111,000 0,340 ,019 
  Wilks’ lambda 0,981 1,090(a) 2,000 111,000 0,340 ,019 
  Hotelling trace 0,020 1,090(a) 2,000 111,000 0,340 ,019 
  Roy’s largest root 0,020 1,090(a) 2,000 111,000 0,340 ,019 
Marital status Pillai’s trace 0,009 0,516(a) 2,000 111,000 0,598 ,009 
  Wilks’ lambda 0,991 0,516(a) 2,000 111,000 0,598 ,009 
  Hotelling trace 0,009 0,516(a) 2,000 111,000 0,598 ,009 
  Roy’s largest root 0,009 0,516(a) 2,000 111,000 0,598 ,009 
Educational 
level 
Pillai’s trace 0,091 5,547(a) 2,000 111,000 0,005 ,091 
  Wilks’ lambda 0,909 5,547(a) 2,000 111,000 0,005 ,091 
  Hotelling trace 0,100 5,547(a) 2,000 111,000 0,005 ,091 
  Roy’s largest root 0,100 5,547(a) 2,000 111,000 0,005 ,091 
Patient’s 
phenotype 
Pillai’s trace 0,065 3,852(a) 2,000 111,000 0,024 ,065 
  Wilks’ lambda 0,935 3,852(a) 2,000 111,000 0,024 ,065 
  Hotelling trace 0,069 3,852(a) 2,000 111,000 0,024 ,065 
  Roy’s largest root 0,069 3,852(a) 2,000 111,000 0,024 ,065 
Patient age Pillai’s trace 0,096 1,878 6,000 224,000 0,086 ,048 
  Wilks’ lambda 0,906 1,879(a) 6,000 222,000 0,085 ,048 
  Hotelling trace 0,103 1,881 6,000 220,000 0,085 ,049 
  Roy’s largest root 0,084 3,132 3,000 112,000 0,028 ,077 
Patient’s 
phenotype * 
Patient age 
Pillai’s trace 0,037 0,711 6,000 224,000 0,641 ,019 
  Wilks’ lambda 0,963 0,705(a) 6,000 222,000 0,646 ,019 
  Hotelling trace 0,038 ,699 6,000 220,000 0,651 ,019 
  Roy’s largest root 0,021 ,788 3,000 112,000 0,503 ,021 
a  Exact statistics 
Bold = effect of covariate variables; bold italic of  independent variables 
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Table 4.5 Levene’s test 
F df1 df2 Sig. 
BDI-II somatic-affective factor 0,802  7 116 0,587 
BDI-II cognitive factor 0,774  7 116 0,610 
 
Table 4.6 Tests of Between-Subjects Effects 
 
Dependent variable 
Sum of 
squares 
type III 
df 
 
Mean 
square 
F 
 
Sig. 
 
Partial 
eta 
squared 
Correct model 
  
BDI-II somatic-
affective factor 
344,981(a) 11 31,362 2,083 0,027 ,170 
  BDI-II cognitive factor 38,396(b) 11 3,491 ,886 0,557 ,080 
Intercept 
  
BDI-II somatic-
affective factor 
64,766 1 64,766 4,302 0,040 ,037 
  BDI-II cognitive factor 8,132 1 8,132 2,063 0,154 ,018 
Gender 
  
BDI-II somatic-
affective factor 
112,921 1 112,921 7,501 0,007 ,063 
  BDI-II cognitive factor 8,520 1 8,520 2,162 0,144 ,019 
Age 
  
BDI-II somatic-
affective factor 
24,393 1 24,393 1,620 0,206 ,014 
  BDI-II cognitive factor ,192 1 ,192 ,049 0,826 ,000 
Marital status 
  
BDI-II somatic-
affective factor 
5,811 1 5,811 ,386 0,536 ,003 
  BDI-II cognitive factor ,209 1 ,209 ,053 0,818 ,000 
Educational 
level 
BDI-II somatic-
affective factor 
11,593 1 11,593 ,770 0,382 ,007 
  BDI-II cognitive 
factor 
14,776 1 14,776 3,749 0,050 ,032 
Patient’s 
phenotype  
BDI-II somatic-
affective factor 
51,018 1 51,018 3,389 0,050 ,029 
  BDI-II cognitive factor ,791 1 ,791 ,201 0,655 ,002 
Patient age 
  
BDI-II somatic-
affective factor 
60,992 3 20,331 1,350 0,262 ,035 
  BDI-II cognitive factor 11,436 3 3,812 ,967 0,411 ,025 
Patient’s 
phenotype * 
Patient age 
BDI-II somatic-
affective factor 
32,997 3 10,999 ,731 0,536 ,019 
  BDI-II cognitive factor 7,509 3 2,503 ,635 0,594 ,017 
Error 
  
BDI-II somatic-
affective factor 
1686,140 112 15,055       
  BDI-II cognitive factor 441,443 112 3,941       
Total 
  
BDI-II somatic-
affective factor 
4237,000 124         
  BDI-II cognitive factor 796,000 124         
Correct total BDI-II somatic-
affective factor 
2031,121 123         
  BDI-II cognitive factor 479,839 123         
a R2=0,17 (R2 adj=0,09); b R2 =0,08 (R2adj = 0,01) 
 Bold = effect of covariate variables; bold italic effect of independent variables 
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Parents of PKU patients, requiring a phe-restricted diet, showed significant higher 
depressive symptoms on the somatic-affective side compared to parents of MHP patients. 
Table 4.7 Effect of being a parents of PKU or MHP patient on BDI factors 
Dependent variables 
Patient’s 
phenotype  
Means 
Std. 
error 
C.I.  95% 
Inferior 
limit 
Superior 
limit 
Inferior 
limit 
Superior 
limit 
BDI-II somatic-affective factor MHP 3,625 0,660 2,317 4,933 
PKU 5,256 0,602 4,065 6,448 
BDI-II cognitive factor MHP 1,567 0,338 ,898 2,236 
PKU 1,364 0,308 ,754 1,974 
 
As regard STAXI, the scale of state-anger could not be normalized; thus, to evaluate the 
effect of the patient’s phenotype and the patient’s age on it non-parametric test was 
performed; Kruskal-Wallis Chi-Squared test was not significant. ANCOVA analysis with 
STAXI Trait-anger scale as dependent variable revealed no effects of socio-demographic 
characteristics, nor of patient’s phenotype, patient’s age or their interaction. MANCOVA 
analysis with STAXI anger expression and control scales as dependent variables revealed 
an effect of educational level on Anger Control-In and Anger Control-Out; no effect of 
patient’s phenotype group, patient’s age or their interaction was found. Means evaluation 
revealed that parents with a primary educational level had a less control of anger 
expression, while graduate parents more frequently tend to control anger. 
MANCOVA analyses with SF-36 dimensions (one with physical and one with mental 
dimensions) were performed. As concern physical dimensions (Physical Functioning 
(activity), Physical Role Functioning, Bodily Pain, General Health) an effect of educational 
level, of the  patient’s phenotype, and of the interaction between patient’s age and patient’s 
phenotype were found (Tables 4.8 – 4.9); of these, the tests of between-subjects effects 
confirmed the role of educational level on Physical functioning (in which parents with a 
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primary educational level showed a lower physical activity) and the interaction effect 
(Table 4.10).  
Table 4.8 Multivariate tests (a) 
Effect 
Value F 
Hypothesis 
df 
Error’s 
df 
Sig. 
Partial 
eta 
squared 
Intercept 
  
  
  
Pillai’s trace 0,603 34,918b 4,000 92,000 0,000 0,603 
Wilks’ lambda 0,397 34,918b 4,000 92,000 0,000 0,603 
Hotelling trace 1,518 34,918
b
 4,000 92,000 0,000 0,603 
Roy’s largest root 1,518 34,918b 4,000 92,000 0,000 0,603 
Gender 
  
  
  
Pillai’s trace 0,065 1,586b 4,000 92,000 0,185 0,065 
Wilks’ lambda 0,935 1,586b 4,000 92,000 0,185 0,065 
Hotelling trace 0,069 1,586
b
 4,000 92,000 0,185 0,065 
Roy’s largest root 0,069 1,586b 4,000 92,000 0,185 0,065 
Age 
  
  
  
Pillai’s trace 0,065 1,608b 4,000 92,000 0,179 0,065 
Wilks’ lambda 0,935 1,608b 4,000 92,000 0,179 0,065 
Hotelling trace 0,070 1,608
b
 4,000 92,000 0,179 0,065 
Roy’s largest root 0,070 1,608b 4,000 92,000 0,179 0,065 
Marital status 
  
  
  
Pillai’s trace 0,078 1,943b 4,000 92,000 0,110 0,078 
Wilks’ lambda 0,922 1,943b 4,000 92,000 0,110 0,078 
Hotelling trace 0,084 1,943
b
 4,000 92,000 0,110 0,078 
Roy’s largest root 0,084 1,943b 4,000 92,000 0,110 0,078 
Educational level 
  
  
  
Pillai’s trace 0,114 2,953b 4,000 92,000 0,024 0,114 
Wilks’ lambda 0,886 2,953b 4,000 92,000 0,024 0,114 
Hotelling trace 0,128 2,953
b
 4,000 92,000 0,024 0,114 
Roy’s largest root 0,128 2,953b 4,000 92,000 0,024 0,114 
Patient’s 
phenotype 
  
  
Pillai’s trace 0,225 1,907 12,000 282,000 0,033 0,075 
Wilks’ lambda 0,788 1,915 12,000 243,701 0,033 0,076 
Hotelling trace 0,253 1,909 12,000 272,000 0,033 0,078 
Roy’s largest root 0,137 3,215 4,000 94,000 0,016 0,120 
Patient age 
  
  
  
Pillai’s trace 0,036 0,848b 4,000 92,000 0,499 0,036 
Wilks’ lambda 0,964 0,848b 4,000 92,000 0,499 0,036 
Hotelling trace 0,037 0,848
b
 4,000 92,000 0,499 0,036 
Roy’s largest root 0,037 0,848b 4,000 92,000 0,499 0,036 
Patient’s 
phenotype * 
Patient age 
Pillai’s trace 0,215 1,818 12,000 282,000 0,045 0,072 
Wilks’ lambda 0,795 1,836 12,000 243,701 0,043 0,073 
Hotelling trace 0,244 1,843 12,000 272,000 0,042 0,075 
Roy’s largest root 0,175 4,111 4,000 94,000 0,004 0,149 
a. Design: Intercept + gender + age + Marital status + Educational level + Patient age + Patient’s phenotype + Patient age 
* Patient’s phenotype - b. Exact statistics. Bold = effect of covariate variable; bold italic effect of  independent variables 
or their interaction. 
42 
 
Table 4.9 Levene’s test 
 F df1 df2 Sig. 
SF36 Physical activity 1,707 7 99 0,116 
SF36 Physical role functioning 3,794 7 99 0,001 
SF36 Bodily pain 1,192 7 99 0,315 
SF36 General Health ,912 7 99 0,501 
 
Table 4.10 Tests of Between-Subjects Effects 
 
Dependent variable 
Sum of 
squares type 
III 
df 
 
Mean 
square 
F 
 
Sig. 
 
Partial 
eta 
squared 
Correct model SF36 Physical activity 1628,860
a
 11 148,078 2,788 0,003 0,244 
SF36 Physical role 
functioning 
4887,216
b
 11 444,292 1,593 0,113 0,156 
SF36 Bodily pain 9338,306
c
 11 848,937 2,006 0,036 0,189 
SF36 General Health 4421,188
d
 11 401,926 1,652 0,097 0,161 
Intercept SF36 Physical activity 7568,035 1 7568,035 142,484 0,000 0,600 
SF36 Physical role 
functioning 
7603,938 1 7603,938 27,268 0,000 0,223 
SF36 Bodily pain 9832,345 1 9832,345 23,239 0,000 0,197 
SF36 General Health 8532,429 1 8532,429 35,063 0,000 0,270 
Gender SF36 Physical activity 22,189 1 22,189 ,418 0,520 0,004 
SF36 Physical role 
functioning 
365,615 1 365,615 1,311 0,255 0,014 
SF36 Bodily pain 2626,569 1 2626,569 6,208 0,014 0,061 
SF36 General Health 196,890 1 196,890 ,809 0,371 0,008 
Age SF36 Physical activity 273,370 1 273,370 5,147 0,026 0,051 
SF36 Physical role 
functioning 
75,497 1 75,497 ,271 0,604 0,003 
SF36 Bodily pain 28,725 1 28,725 ,068 0,795 0,001 
SF36 General Health 4,252 1 4,252 ,017 0,895 0,000 
Marital status SF36 Physical activity 163,266 1 163,266 3,074 0,083 0,031 
SF36 Physical role 
functioning 
98,934 1 98,934 ,355 0,553 0,004 
SF36 Bodily pain 2394,735 1 2394,735 5,660 0,019 0,056 
SF36 General Health 1153,980 1 1153,980 4,742 0,032 0,048 
Educational 
level 
SF36 Physical activity 565,022 1 565,022 10,638 0,002 0,101 
SF36 Physical role 
functioning 
793,632 1 793,632 2,846 0,095 0,029 
SF36 Bodily pain 551,296 1 551,296 1,303 0,257 0,014 
SF36 General Health 101,098 1 101,098 ,415 0,521 0,004 
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Patient age SF36 Physical activity 198,635 3 66,212 1,247 0,297 0,038 
SF36 Physical role 
functioning 
3062,496 3 1020,832 3,661 0,015 0,104 
SF36 Bodily pain 3353,968 3 1117,989 2,642 0,054 0,077 
SF36 General Health 2660,008 3 886,669 3,644 0,015 0,103 
Patient’s 
phenotype  
SF36 Physical activity 94,023 1 94,023 1,770 0,187 0,018 
SF36 Physical role 
functioning 
202,653 1 202,653 ,727 0,396 0,008 
SF36 Bodily pain 1252,588 1 1252,588 2,961 0,089 0,030 
SF36 General Health 94,184 1 94,184 ,387 0,535 0,004 
Patient age * 
Patient’s 
phenotype  
 
SF36 Physical activity 757,673 3 252,558 4,755 0,004 0,131 
SF36 Physical role 
functioning 
1748,482 3 582,827 2,090 0,107 0,062 
SF36 Bodily pain 1733,592 3 577,864 1,366 0,258 0,041 
SF36 General Health 2167,606 3 722,535 2,969 0,036 0,086 
Error SF36 Physical activity 5045,906 95 53,115    
SF36 Physical role 
functioning 
26491,289 95 278,856    
SF36 Bodily pain 40193,881 95 423,093    
SF36 General Health 23117,784 95 243,345    
Total SF36 Physical activity 973300,000 107     
SF36 Physical role 
functioning 
924375,000 107     
SF36 Bodily pain 671675,000 107     
SF36 General Health 584822,000 107     
Correct total  SF36 Physical activity 6674,766 106     
SF36 Physical role 
functioning 
31378,505 106     
SF36 Bodily pain 49532,187 106     
SF36 General Health 27538,972 106     
a. R
2
 = 0,244 (R
2
 adj = 0,156); b. R
2
 = 0,156 (R
2
 adj = 0,058); c. R
2
 = 0,189 (R
2
 adj = 0,095); d. R
2
 = 0,161 
(R
2
 adj = 0,063) - Bold = effect of covariate variables; bold italic of  independent variables or their interaction. 
 
 
The interaction was significant for Physical functioning (activity) and General health 
SF-36 subscales (Figures 4.7 and 4.8). While quality of life of parents of MHP patients 
fluctuated a little until the scholar stage and then markedly improve, quality of life of PKU 
parents slightly decreased. 
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Figure 4.7 Effect of the interaction between patient’s phenotype group and patient’s age  
on Physical functioning SF-36 subscale 
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Figure 4.8 Effect of the interaction between patient’s phenotype group and patient’s age  
on General health SF-36 subscale 
 
 
As concern the SF-36 dimensions regarding the emotional wellbeing (Vitality, Social 
Functioning, Emotional Role Functioning and Mental Health), the MANOVA analysis 
revealed no effects of socio-demographic characteristics (except for gender, in the direction 
already described above), nor of patient’s phenotype group, patient’s age or their interaction 
(Table 4.11). 
46 
 
Table 4.11 Multivariate tests (a) 
Effect Value F Hypothesis 
df 
Error’s df Sig. 
Intercept 
  
  
  
Pillai’s trace 0,165 5,576b 4,000 113,000 0,000 
Wilks’ lambda 0,835 5,576b 4,000 113,000 0,000 
Hotelling trace 0,197 5,576b 4,000 113,000 0,000 
Roy’s largest root 0,197 5,576b 4,000 113,000 0,000 
Gender 
  
  
  
Pillai’s trace 0,129 4,173b 4,000 113,000 0,003 
Wilks’ lambda 0,871 4,173b 4,000 113,000 0,003 
Hotelling trace 0,148 4,173b 4,000 113,000 0,003 
Roy’s largest root 0,148 4,173b 4,000 113,000 0,003 
Age 
  
  
  
Pillai’s trace 0,004 0,104b 4,000 113,000 0,981 
Wilks’ lambda 0,996 0,104b 4,000 113,000 0,981 
Hotelling trace 0,004 0,104b 4,000 113,000 0,981 
Roy’s largest root 0,004 0,104b 4,000 113,000 0,981 
Marital status 
  
  
  
Pillai’s trace 0,017 0,485b 4,000 113,000 0,747 
Wilks’ lambda 0,983 0,485b 4,000 113,000 0,747 
Hotelling trace 0,017 0,485b 4,000 113,000 0,747 
Roy’s largest root 0,017 0,485b 4,000 113,000 0,747 
Educational level 
  
  
  
Pillai’s trace 0,035 1,017b 4,000 113,000 0,402 
Wilks’ lambda 0,965 1,017b 4,000 113,000 0,402 
Hotelling trace 0,036 1,017b 4,000 113,000 0,402 
Roy’s largest root 0,036 1,017b 4,000 113,000 0,402 
Patient’s phenotype  
  
  
Pillai’s trace 0,067 0,659 12,000 345,000 0,790 
Wilks’ lambda 0,934 0,652 12,000 299,261 0,797 
Hotelling trace 0,069 0,645 12,000 335,000 0,803 
Roy’s largest root 0,040 1,144c 4,000 115,000 0,339 
Patient age 
  
  
  
Pillai’s trace 0,006 0,182b 4,000 113,000 0,947 
Wilks’ lambda 0,994 0,182b 4,000 113,000 0,947 
Hotelling trace 0,006 0,182b 4,000 113,000 0,947 
Roy’s largest root 0,006 0,182b 4,000 113,000 0,947 
Patient’s phenotype * 
Patient age 
Pillai’s trace 0,036 0,348 12,000 345,000 0,979 
Wilks’ lambda 0,964 0,345 12,000 299,261 0,980 
Hotelling trace 0,037 0,343 12,000 335,000 0,980 
Roy’s largest root 0,032 0,915c 4,000 115,000 0,458 
a. Design: Intercept + gender + age + Marital status + Educational level + Patient age + Patient’s phenotype  + Patient 
age * Patient’s phenotype  
b. Exact statistics 
Bold = effect of covariate variable 
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4.6 Compliance to diet in PKU patients 
In the 86 parents of PKU patients (on a phe-restricted diet), means of blood phe levels 
were 378,19 μmol/L (s.d. 246,85, range 77-1247 μmol/L). With the cut-off of the target 
blood phe levels by age group (Blau et al., 2010), 73% (n=63) were adherent to diet while 
27% (n=23) had high phe levels indicating a poor metabolic control in relation to a poor 
dietary compliance. 
Patients’ phe level positively correlated with patient age (r=0.67, p<0.001): that is, 
adolescent and young adult showed the worse compliance to diet (Figure 4.12).  
 
Figure 4.12 Blood phenylalanine levels increase with patient age 
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There were no differences between parents of adherent patients and parents of non-
adherent patients for the socio-demographic characteristics. 
Logistic regressions were performed to test if parental psychological and QoL outcomes 
predict PKU patients’ compliance to dietary regimen; the results are summarized below.  
 
4.6.1 Relationship between parental psychological issues and patients’ Phe levels  
Patients optimal phe levels and thus patients’ good compliance to the dietary regimen was 
found to be predicted by specific parental psychological characteristics, that globally 
explained the 34% of variance. In particular, parents how showed high levels of somatic-
affective component (=1.52, p=0.011) and low levels of cognitive component (=0.59, 
p=0.050) of depressive complaints, high level of anger control (=0.77, p=0.043) and low 
level of anger expression outward (=1.35, p=0.032) more frequently had adherent 
sons/daughters (see tables below). 
 
Omnibus Tests of Model Coefficients 
 
    Chi-squared df Sig. 
Step 1 Step 19,836 10 0,031 
  Block 19,836 10 0,031 
  Model 19,836 10 0,031 
 
 
Model summary 
 
Step -2 Log likelihood Cox & Snell R
2
 Nagelkerke R
2
 
1 66,772 0,225 0,335 
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Classification table (a) 
 
  Observed Predicted 
    Adherence 01 Percentage correct 
    0 1 0 
Step 1 Adherence 01 0 7 12 36,8 
    1 3 56 94,9 
  Overall percentage     80,8 
a  The cut value is 0,500 
 
Variables in the equation 
 
  B E.S. Wald df Sig. Exp(B) 
Step 
1(a) 
SCL90_GSI 
2,628 1,607 2,674 1 0,102 13,846 
  STAY_State 0,003 0,051 0,003 1 0,954 1,003 
  STAY_Trait -0,041 0,065 0,398 1 0,528 0,960 
  BDI_II_Somatic_Affective 0,420 0,165 6,510 1 0,011 1,522 
  BDI_II_Cognitive -0,519 0,267 3,783 1 0,050 0,595 
  STAXI_RT 0,216 0,137 2,478 1 0,115 1,241 
  STAXI_ER_OUT -0,259 0,128 4,103 1 0,043 0,772 
  STAXI_ER_IN -0,109 0,103 1,133 1 0,287 0,897 
  STAXI_CR_OUT 0,299 0,140 4,580 1 0,032 1,349 
  STAXI_CR_IN -0,284 0,128 4,894 1 0,057 0,753 
  Costante 2,806 2,991 0,880 1 0,348 16,547 
a  Variables entered in step 1: SCL90_GSI, STAY_State, STAY_Trait, BDI_II_Somatic_Aff, 
BDI_II_Cognitive, STAXI_RT, STAXI_ER_OUT, STAXI_ER_IN, STAXI_CR_OUT, STAXI_CR_IN. 
 
4.6.2 Relationship between parental quality of life and patients’ Phe levels  
Patients optimal phe levels was found to be predicted also by some of the parental quality 
of life dimensions, which globally explained the 25% of variance. In particular, parents 
how showed a lower Vitality (=0.93, p=0.035) and a lower Social functioning (=0.94, 
p=0.027) and a higher Mental health (=1.07, p=0.043) more frequently had adherent 
sons/daughters (see tables below). 
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Omnibus Tests of Model Coefficients 
 Chi-squared df Sig. 
Step 1 Step 15,223 8 0,055 
Block 15,223 8 0,055 
Model 15,223 8 0,055 
 
Model summary 
Step -2 Log likelihood Cox & Snell R
2
 Nagelkerke R
2
 
1 81,434 0,171 0,246 
 
 
Classification table (a) 
 
  Observed 
Predicted 
Adherence 01 Percentage 
correct 0 1 
Step 1 Adherence 01 0 8 15 34,8 
1 2 56 96,6 
Overall percentage     79,0 
a  The cut value is 0,500 
 
 
Variables in the equation 
 B E.S. Wald df Sig. Exp(B) 
Step 1
a
 SF36 Physical activity -0,028 0,027 1,074 1 0,300 0,973 
SF36 Physical role functioning -0,003 0,017 0,028 1 0,867 0,997 
SF36 Bodily pain 0,010 0,018 0,314 1 0,575 1,010 
SF36 General health 0,030 0,020 2,189 1 0,139 1,030 
SF36 Vitality -0,066 0,031 4,469 1 0,035 0,936 
SF36 Social functioning -0,053 0,024 4,898 1 0,027 0,948 
SF36 Emotional role functioning 0,015 0,015 0,928 1 0,335 1,015 
SF36 Mental health 0,068 0,034 4,081 1 0,043 1,071 
Costante 3,368 2,222 2,298 1 0,130 29,024 
a. Variables entered in step 1: SF36_AF, SF36_RF, SF36_DF, SF36_SG, SF36_VT, SF36_AS, SF36_RE, 
SF36_SM. 
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5. DISCUSSION 
The current investigation focused on psychological wellbeing and quality of life among 
parents of patients with phenylketonuria. The first aim of the study was to describe the 
parental psychological characteristics and quality of life; the second aim was to evaluate 
the influence of parental psychological issues on patients’ compliance to dietary regimen.  
Globally, parents showed psychological characteristics and quality of life comparable to 
the normative sample. This finding is remarkable because of the potential substantial 
burden of the disease on the family (Kazak et al. 1988), due to the stress and the added 
responsibilities associated with a metabolic disorder and its treatment. As a whole parents 
under study were functioning quite well, showing a good psychological adaptation and a 
positive perception of their quality of life, which is consistent to previous studies showing 
that mental wellbeing and health related quality of life of the parents are almost normal 
(Bosch et al., 2015; Blumenthal, 1967; Fidika et al., 2013; Fisch et al., 1981; ten Hoedt et 
al., 2011;). Several explanations for the relatively high reported wellbeing of the parents 
are conceivable. Compared to other pediatric chronic or life threatening conditions 
(diabetes, congenital heart disease, lysosomal storage diseases, etc.), PKU is highly 
responsive to treatment. Therefore the course and the life expectancy are very promising. 
Another considerable fact could be that the participating parents are selected from one of 
the main referenced centres that provides management for PKU children, that have a 
medical team specifically trained in counselling and include a psychologist who follows all 
the developmental stages of children and goes along with parents. 
Despite the general good adaptation observed, a percentage of parents reported critical 
issues: clinical psychological distress, state and trait anxiety, depressive symptoms, and an 
impact on various quality of life domains both in the psychical and in the emotional fields. 
Moreover, parents showed a tendency to hyper-control the expression of anger. As yet 
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little attention has been paid to the feeling of anger and aggressiveness in parents of PKU 
children;  this gap in knowledge is of concern, given the common parental reactions of 
anger towards their child’s chronic illness. So the evaluation of anger and anger reactions 
conducted in our research is a strength-point. 
These maladjustments seem to be related to specific parents’ socio-demographic or 
patients’ clinical conditions. 
Mothers are more at risk of developing psychological maladjustment as they scored 
higher on almost all the scales evaluating the emotional well-being. The results are 
consistent with previous studies both on PKU (Kazak, 1987; Lord et al., 2005, 2008) and 
other chronic illness showing a greater impact on mothers than fathers (Barlow & Ellard, 
2006). This discrepancy may reflect gender differences on self-reporting emotional issues 
in the general population or may due to the fact that mothers are the main caregiver of 
children and so are the most frequently burdened by the disease and treatment 
management. 
Lower educational level is associated with higher depressive symptoms on the cognitive 
domains, a lower control of anger expression and a lower physical functioning. These data 
are consistent with previous literature exploring the role of educational level on emotional 
wellbeing: lower-educated individuals may be less able to deal with psychological stress 
and burdens because they have a weaker internal locus of control, lower levels of social 
support, and more passive coping strategies (Kristenson et al., 2004; Schieman & Plickert, 
2008). 
The dietary regimen plays a burdening role on the emotional wellbeing of parents. We 
have highlighted the load of dietary treatment comparing parents of PKU children (who 
have to follow a phe-restricted diet) and parents of MHP children (who not need to be 
treated). Parents of PKU patients reported more depressive symptoms on the somatic-
affective side (also with the parent gender as a covariate; that is, the effect is not due to 
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mothers) and showed a lower quality of life, in particular in later developmental stages of 
their sons/daughters (pre-adolescence, adolescence and young adulthood). That is, a good 
emotional wellbeing is acquired earlier by parents of patients whose disease phenotype do 
not impact on the dietary management. To our knowledge, the effort we have done trying 
to distinguish the impact of having the diagnosis of phenylketonuria from the load of the 
dietary management on parental wellbeing comparing PKU and MHP is the first attempt 
and is a strength-point of our research. 
The second aim of the present study was to evaluate (obviously only among parents of 
PKU patients) the role of parental psychological issues on blood phenylalanine levels, that 
reflect the metabolic control and the dietary compliance. First of all, the majority of PKU 
patients showed an optimal compliance to the diet; nevertheless, a non marginal percentage 
(27%) of them resulted non adherent. Moreover, a robust positive correlation between age 
and phenylalanine levels was found, that in other words means that adherence to diet 
decrease with age; this trend has also been found in the diabetes literature (Anderson et al., 
1997). The need to be part of a peer group is a salient developmental phenomenon during 
adolescence and this need can conflict with dietary regimen; in fact a great part of 
adolescents with chronic health conditions fail to adhere to treatment recommendations 
(Kyngäs et al., 2000).  
Our data pointed out an association between parental psychological issues and the 
metabolic control that reflects a dietary compliance. Few studies has previously tried to 
link parents’ functioning to metabolic control in phenylketonuria but they have led to 
inconclusive data (Olsson et al., 2007; Reber et al., 1987). These results are similar to other 
studies in the field diabetes that have shown that family factors play a role in adherence 
behaviors, with family conflict and self-management competence emerging as important 
predictors of non-adherence to treatment and metabolic control (Anderson et al., 1999; 
Hauser et al., 1990; Miller-Johnson et al., 1994). What we have found is partially in 
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agreement and partially in discordance with the hypothesis that a parental emotional 
maladjustments are associated to lower adherence. In fact, we found that a good adherence 
to diet is predicted by a good mental health and less depressive symptoms on the cognitive 
side together with a tendency to control and repress anger expression outward; 
surprisingly, optimal compliance was also predicted by more depressive symptoms on the 
somatic side, less vitality and a lower social functioning. 
These results convey various reflections.  
First, psychological adjustment of parents seems to be important for children to follow 
the diet prescriptions, as similar to the literature on other chronic conditions (Chaney & 
Peterson, 1989; Christensen et al., 1992; Davis et al., 2001; Hauser et al., 1990; Miller-
Johnson et al., 1994).  
Second, expressing anger does not pay in terms of adherence to treatment. Parents 
probably repress their feeling of anger adopting a controlling modality of anger expression 
outward. Perhaps, the same controlling-modality grounds a successful management of the 
dietary treatment leading to an optimal adherence. 
Third, in some way, adherence to the diet appears to be an emotional cost for parents. In 
fact, adherence is maintained optimal at the expense of parental vitality, social activities 
and the possibility to express emotional feelings (including angry) that results in 
somatisations. 
Finally, our study seems to pointed out the role and the impact on parents’ social 
functioning, but in a new perspective. Previous studies has stressed the importance of 
social support and social network as protective factors for the emotional wellbeing of 
parents of PKU children (Lord et al., 2005; ten Hoedt et al., 2011) if not even a signal of 
successful adaptation to the disease and treatments (Kazak, 1987). In our study parents of 
adherent patients are those who showed a great impact on social activities; that is, the cost 
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that parents pay to help their sons/daughters to remain adherent to dietary regimen is the 
reduction of social activities. 
As already pointed out directly from patients words in a previous study (Vegni et al., 
2009), PKU seems to be like a disease that is not visible except for the social occasions in 
which the illness becomes manifest, presenting itself as a social disease. The paradox that 
PKU patients’, and probably their parents, has to face is therefore between either being 
healthy and normal (maintaining an optimal adherence to diet) but isolated from the social 
context, or being seen as different if they do not decide to give up the convivial aspects that 
profoundly characterize the social relations. 
 
5.1 Practice implications 
The findings of the present study have several implications for clinical practice.  
Results are useful to help clinicians to identify specific situations at risk for non 
adherence and may have implications for setting up interventions to improve compliance to 
diet.  
A relationship exists between children metabolic control and parental wellbeing; the 
higher depressive symptoms on the cognitive side, anger expression outward and mental 
stress in parents, the more likely their children showed phenylalanine level reflecting non 
adherence. Parents at risk for psychological or quality of life disturbances should be 
referred to psycho-educational group programs to take a survey of the problems and to 
empower parents to set up or maintain an adequate well-being, child adherence but not at 
the expense of social activities and functioning. 
Parental mental functioning influences not only compliance to diet but also the health, 
development and adjustment of their children (Prince et al., 2007), and this is particularly 
important with children with chronic disorders that are vulnerable to develop adjustment 
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problems when compared to their healthy peers (Pless & Nolan, 1991; Wallander & Varni, 
1998); moreover, blood phenylalanine levels are related to patients psychological 
wellbeing, since high levels are associated with mood and behavioural disorders. 
Therefore, it is important that physicians involved in the care of children with PKU also 
pay attention to the well-being of the parents. 
 
5.2 Limits 
There are a few limitations of the current study which should be acknowledged. For 
example, our sample size was relatively small. Moreover, the fact that no data on reasons 
for declining participation were available might conceal a self-selection of less or more 
stressed parents within the study group. The study is monocentric and participants were all 
selected in one of the referred centre in Italy for PKU: potentially we gather parents 
coming from different cultural context and regions but probably are parents a little bit more 
adapted to their child disease because of the quality of care provided.. Notwithstanding 
these limitations, our study group has a considerable sample size and is representative to a 
certain extent for all parents of children with PKU. The absence of a comparison group of 
parents with children with other chronic conditions does not allow drawing any conclusion 
about the specificity for the group of parents of children with PKU. 
 
5.3 Future directions 
As we have highlighted the role of phenylketonuria on parents wellbeing, it could be 
important to consider also some relational aspects of these parents; new areas of interest 
could be the relationship with the partner and the relationship with the ill child, in terms of 
attachment. 
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Because of previous inconstant results, it would be interesting to examine the impact of 
parenting a child with phenylketonuria on marital relationship and on parental social 
networks, both within and outside family. 
As far as attachment research, the literature has stressed the importance of parental 
psychological adjustment as an essential factor both for the structuring of a secure parent-
child relationship and for chronically ill child’s psychological adjustment. In fact, parental 
psychological adjustment, that is coping abilities, emotional state and attitudes toward a 
sick child and the illness, can influence children’s psychological adjustment through 
relations with a child. It could be very interesting to evaluate the effect of parents’ 
psychological wellbeing on parent-child relationship, in term of the type of the developed 
attachment relation exploring which factors are associated with a secure attachment in 
phenylketonuric families. 
 
6. CONCLUSIONS  
Parenting children with phenylketonuria do not affect psychological wellbeing or 
quality of life. Maladjustments arise in specific socio-demographic conditions, and are 
mainly related to the dietary management load and to the effort of maintaining an optimal 
adherence. Help children to remain adherent to the dietary seems to affect the parents’ 
social functioning.  
Our data seem to point in the direction of seeing psychological disturbances in parents 
of PKU patients from a psychosocial perspective (one of the possible perspective stated in 
the first chapter): PKU amounts to a chronic disease that requires a rigorous therapeutic 
treatment in which parental involvement is very heavy and burdensome, with implications 
for parents’ psychological wellbeing and quality of life. 
58 
 
We can conclude that parental psychological wellbeing and quality of life is of utmost 
importance to consider when dealing with patients with phenylketonuria. On the one hand, 
children learn to adjust and cope from their parents. On the other hand, parental 
disturbances can restrict their ability to satisfy children’s social and emotional needs. 
Moreover, parental distress can negatively affect adherence to treatment requirements. 
Increase of the concentration of phenylalanine in child’s organism, as a result, may directly 
influence child’s mental health, that is cognitive and emotional functioning. Thus, the 
evaluation of the impact of parenting a PKU child could provide useful insights to set up 
prevention programs and to improve parents wellbeing, parent-child relationships and 
patients adjustment, in particular in specific critical conditions. 
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